Earnings History Data for IN8bio (INAB) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

IN8bio

IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.

Release Date	Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	AH	INAB	IN8bio	16.00	-0.15	-0.14	0.00	IN8bio GAAP EPS of -$0.15 [11/13/2024 12:43 PM]	0.3193	-0.03 (-8.75%)	0.33	-0.02 (-5.69%)	0.22 - 2.48	555,201	1,240,000	137,275
IN8bio GAAP EPS of -$0.15 [11/13/2024 12:43 PM] IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Nov-12-24 04:26PM] IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting [Nov-12-24 07:00AM]
08-08-2024	PM	INAB	IN8bio, Inc.	31.46	-0.19	-0.16	-0.27	IN8bio GAAP EPS of -$0.19 [8/9/2024 7:22 AM]	0.6841	0.0 (0.00%)	0.70	0.02 (2.32%)	0.65 - 2.48	43,088	80,000	2,763
IN8bio GAAP EPS of -$0.19 [8/9/2024 7:22 AM]
14-03-2024	AH	INAB	IN8bio	41.00	-0.21	-0.16	0.00	IN8bio GAAP EPS of -$0.22 [3/14/2024 5:54 PM]	1.19	0.03 (2.59%)	1.17	0.01 (0.86%)	0.65 - 3.95	112,098	190,000	1,371
IN8bio GAAP EPS of -$0.22 [3/14/2024 5:54 PM]
30-03-2023	PM	INAB	IN8bio, Inc.	44.10	-0.32	-0.28	-0.21	IN8bio GAAP EPS of -$0.32 in-line [3/31/2023 12:42 AM]	1.30	0.0 (0.00%)	0.0	0.0 (0.00%)	1.12 - 4.98	23,249	80,000	0
IN8bio GAAP EPS of -$0.32 in-line [3/31/2023 12:42 AM]
12-08-2022	AH	INAB	IN8bio	41.00	-0.38	-0.33	0.00	IN8bio GAAP EPS of -$0.38 [8/12/2022 4:54 PM]	1.88	0.03 (1.62%)	1.94	-0.04 (-2.02%)	1.84 - 9.50	94,120	40,000	21,442
IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock [Aug-11-22 10:05PM] IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update [Aug-12-22 04:15PM]
12-05-2022	PM	INAB	IN8bio	49.00	-0.33	-0.34	0.00	IN8bio Q1 GAAP EPS of -$0.33 [5/12/2022 8:31 AM]	2.25	0.0 (0.00%)	0.0	0.0 (0.00%)	2.00 - 10.32	19,127	20,000	0
IN8bio Q1 GAAP EPS of -$0.33 [5/12/2022 8:31 AM] IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update [May-12-22 08:00AM]
17-03-2022	AH	INAB	IN8bio, Inc.	59.08	-0.21	0.00	0.00	IN8bio GAAP EPS of -$0.44 [3/17/2022 4:49 PM]	2.98	-0.04 (-1.16%)	3.02	0.0 (0.00%)	2.44 - 10.32	39,115	40,967	0
IN8bio GAAP EPS of -$0.44 [3/17/2022 4:49 PM] IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update [Mar-17-22 04:15PM]
10-11-2021	AH	INAB	IN8bio	159.00	-0.25	-0.33	0.00	IN8bio reports Q3 results [11/10/2021 5:13 PM]	8.01	-0.54 (-6.32%)	0.0	0.0 (0.00%)	5.76 - 10.32	53,548	30,000	0
IN8bio reports Q3 results [11/10/2021 5:13 PM] IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update [Nov-10-21 04:15PM] IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpoint Inhibitors in Solid Tumors [Nov-11-21 07:00AM]